AMP-Activated protein kinase, fatty acid metabolism, and insulin sensitivity

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 20, Issue 4, 2017, Pages 248-253

  Smith, Brennan K ^a   Steinberg, Gregory R ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

acetyl CoA carboxylase; AMP Activated protein kinase; de novo lipogenesis; fatty acid metabolism; insulin resistance; mitochondria

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ACTIVATOR; FATTY ACID;

ADIPOSE TISSUE; DRUG MECHANISM; ENZYME ACTIVATION; ESTERIFICATION; FATTY ACID METABOLISM; FATTY ACID OXIDATION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPOGENESIS; MITOCHONDRION; NONHUMAN; REVIEW; ANIMAL; DRUG EFFECTS; LIVER; METABOLISM; PHYSIOLOGY; ULTRASTRUCTURE;

ADIPOSE TISSUE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ENZYME ACTIVATION; FATTY ACIDS; HUMANS; INSULIN RESISTANCE; LIPOGENESIS; LIVER; MITOCHONDRIA;

EID: 85017113990     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0000000000000380     Document Type: Review

References (52)

1. Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med 2014; 371:1131-1141.
2. Ruderman NB, Carling D, Prentki M, Cacicedo JM. AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest 2013; 123:2764-2772.
3. Carling D. AMPK signalling in health and disease. Curr Opin Cell Biol 2017; 45:31-37.
4. Smith BK, Marcinko K, Desjardins EM, et al. Treatment of nonalcoholic fatty liver disease: role of AMPK. Am J Physiol Endocrinol Metab 2016; 311:E730-E740.
5. Gowans GJ, Hawley SA, Ross FA, Hardie DG. AMP is a true physiological regulator of AMP-Activated protein kinase by both allosteric activation and enhancing net phosphorylation. Cell Metab 2013; 18:556-566.
6. Hardie DG. AMPK: A target for drugs and natural products with effects on both diabetes and cancer. Diabetes 2013; 62:2164-2172.
7. Fullerton MD, Galic S, Marcinko K, et al. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat Med 2013; 19:1649-1654.
8. ONeill HM, Lally JS, Galic S, et al. AMPK phosphorylation of ACC2 is required for skeletal muscle fatty acid oxidation and insulin sensitivity in mice. Diabetologia 2014; 57:1693-1702.
9. Kjobsted R, Treebak JT, Fentz J, et al. Prior AICAR stimulation increases insulin sensitivity in mouse skeletal muscle in an AMPK-dependent manner. Diabetes 2015; 64:2042-2055.
10. Kjobsted R, Munk-Hansen N, Birk JB, et al. Enhanced muscle insulin sensitivity after contraction/exercise is mediated by AMPK. Diabetes 2017; 66:598-612.
11. Chen Q, Xie B, Zhu S, et al. A Tbc1d1 Ser231Ala-knockin mutation partially impairs AICAR-but not exercise-induced muscle glucose uptake in mice. Diabetologia 2017; 60:336-345.
12. Liu Y, Lai YC, Hill EV, et al. Phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) is an AMPK target participating in contraction-stimulated glucose uptake in skeletal muscle. Biochem J 2013; 455:195-206.
13. Bujak AL, Crane JD, Lally JS, et al. AMPK activation of muscle autophagy prevents fasting-induced hypoglycemia and myopathy during aging. Cell Metab 2015; 21:883-890.
14. Marcinko K, Bujak AL, Lally JS, et al. The AMPK activator R419 improves exercise capacity and skeletal muscle insulin sensitivity in obese mice. Mol Metab 2015; 4:643-651.
15. Vernochet C, Damilano F, Mourier A, et al. Adipose tissue mitochondrial dysfunction triggers a lipodystrophic syndrome with insulin resistance, hepatosteatosis, and cardiovascular complications. FASEB J 2014; 28:4408-4419.
16. Kim JY, van de Wall E, Laplante M, et al. Obesity-Associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 2007; 117:2621-2637.
17. Cuthbertson DJ, Steele T, Wilding JP, et al. What have human experimental overfeeding studies taught us about adipose tissue expansion and susceptibility to obesity and metabolic complications? Int J Obes (Lond) 2017.
18. Chondronikola M, Volpi E, Borsheim E, et al. Brown adipose tissue improves whole-body glucose homeostasis and insulin sensitivity in humans. Diabetes 2014; 63:4089-4099.
19. Crane JD, Palanivel R, Mottillo EP, et al. Inhibiting peripheral serotonin synthesis reduces obesity and metabolic dysfunction by promoting brown adipose tissue thermogenesis. Nat Med 2015; 21:166-172.
20. Toyama EQ, Herzig S, Courchet J, et al., Metabolism. AMP-Activated protein kinase mediates mitochondrial fission in response to energy stress. Science 2016; 351:275-281.
21. Ducommun S, Deak M, Sumpton D, et al. Motif affinity and mass spectrometry proteomic approach for the discovery of cellular AMPK targets: identification of mitochondrial fission factor as a new AMPK substrate. Cell Signal 2015; 27:978-988.
22. Schaffer BE, Levin RS, Hertz NT, et al. Identification of AMPK phosphorylation sites reveals a network of proteins involved in cell invasion and facilitates large-scale substrate prediction. Cell Metab 2015; 22: 907-921.
23. Marin TL, Gongol B, Zhang F, et al. AMPK promotes mitochondrial biogenesis and function by phosphorylating the epigenetic factors DNMT1, RBBP7, and HAT1. Sci Signal 2017; 10:pii: eaaf7478.
24. Zhang H, Guan M, Townsend KL, et al. MicroRNA-455 regulates brown adipogenesis via a novel HIF1an-AMPK-PGC1alpha signaling network. EMBO Rep 2015; 16:1378-1393.
25. Yang Q, Liang X, Sun X, et al. AMPK/alpha-ketoglutarate axis dynamically mediates DNA demethylation in the Prdm16 promoter and brown adipogenesis. Cell Metab 2016; 24:542-554.
26. Perdikari A, Kulenkampff E, Rudigier C, et al. A high-Throughput, image-based screen to identify kinases involved in brown adipocyte development. Sci Signal 2017; 10.
27. Mottillo EP, Desjardins EM, Crane JD, et al. Lack of adipocyte AMPK exacerbates insulin resistance and hepatic steatosis through brown and beige adipose tissue function. Cell Metab 2016; 24:118-129.
28. Henriksen BS, Curtis ME, Fillmore N, et al. The effects of chronic AMPK activation on hepatic triglyceride accumulation and glycerol 3-phosphate acyltransferase activity with high fat feeding. Diabetol Metab Syndr 2013; 5:29.
29. Hasenour CM, Ridley DE, Hughey CC, et al. 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR) effect on glucose production, but not energy metabolism, is independent of hepatic AMPK in vivo. J Biol Chem 2014; 289:5950-5959.
30. Sato S, Jung H, Nakagawa T, et al. Metabolite regulation of nuclear localization of carbohydrate response element-binding protein (ChREBP). Role of AMP as an allosteric inhibitor. J Biol Chem 2016; 291:10515-10527.
31. Miller RA, Chu Q, Xie J, et al. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 2013; 494:256-260.
32. Langendorf CG, Ngoei KR, Scott JW, et al. Structural basis of allosteric and synergistic activation of AMPK by furan-2-phosphonic derivative C2 binding. Nat Commun 2016; 7:10912.
33. Hunter RW, Foretz M, Bultot L, et al. Mechanism of action of compound-13: An alpha1-selective small molecule activator of AMPK. Chem Biol 2014; 21:866-879.
34. Wu C, Guo Y, Su Y, et al. Cordycepin activates AMP-Activated protein kinase (AMPK) via interaction with the gamma1 subunit. J Cell Mol Med 2014; 18:293-304.
35. Cool B, Zinker B, Chiou W, et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab 2006; 3:403-416.
36. Xiao B, Sanders MJ, Carmena D, et al. Structural basis of AMPK regulation by small molecule activators. Nat Commun 2013; 4:3017.
37. Zadra G, Photopoulos C, Tyekucheva S, et al. A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. EMBO Mol Med 2014; 6:519-538.
38. Scott JW, Galic S, Graham KL, et al. Inhibition of AMP-Activated protein kinase at the allosteric drug-binding site promotes islet insulin release. Chem Biol 2015; 22:705-711.
39. Pinkosky SL, Newton RS, Day EA, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun 2016; 7:13457.
40. Vincent EE, Coelho PP, Blagih J, et al. Differential effects of AMPK agonists on cell growth and metabolism. Oncogene 2015; 34:3627-3639.
41. Hawley SA, Fullerton MD, Ross FA, et al. The ancient drug salicylate directly activates AMP-Activated protein kinase. Science 2012; 336: 918-922.
42. Ford RJ, Fullerton MD, Pinkosky SL, et al. Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity. Biochem J 2015; 468:125-132.
43. Lai YC, Kviklyte S, Vertommen D, et al. A small-molecule benzimidazole derivative that potently activates AMPK to increase glucose transport in skeletal muscle: comparison with effects of contraction and other AMPK activators. Biochem J 2014; 460:363-375.
44. Pinkosky SL, Filippov S, Srivastava RA, et al. AMP-Activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res 2013; 54:134-151.
45. Cameron KO, Kurumbail RG. Recent progress in the identification of adenosine monophosphate-Activated protein kinase (AMPK) activators. Bioorg Med Chem Lett 2016; 26:5139-5148.
46. Yang X, Mudgett J, Bou-About G, et al. Physiological expression of AMPKgamma2RG mutation causes Wolff-Parkinson-White syndrome and induces kidney injury in mice. J Biol Chem 2016; 291: 23428-23439.
47. Yavari A, Stocker CJ, Ghaffari S, et al. Chronic activation of gamma2 AMPK induces obesity and reduces beta cell function. Cell Metab 2016; 23: 821-836.
48. Hulsmeier AJ, Tobler M, Burda P, Hennet T. Glycosylation site occupancy in health, congenital disorder of glycosylation and fatty liver disease. Sci Rep 2016; 6:33927.
49. Sayej WN, Knight Iii PR, Guo WA, et al. Advanced glycation end products induce obesity and hepatosteatosis in CD-1 wild-Type mice. Biomed Res Int 2016; 2016:7867852.
50. Solinas G, Boren J, Dulloo AG. De novo lipogenesis in metabolic homeostasis: more friend than foe? Mol Metab 2015; 4:367-377.
51. Chow JD, Lawrence RT, Healy ME, et al. Genetic inhibition of hepatic acetyl-CoA carboxylase activity increases liver fat and alters global protein acetylation. Mol Metab 2014; 3:419-431.
52. Lee J, Kim Y, Friso S, Choi SW. Epigenetics in nonalcoholic fatty liver disease. Mol Aspects Med 2016; 54:78-88.